Physician profile
Wallace Thomas
NPI 1831490432
$10,472.82
in general payments reported to CMS, 2019-2025
17 companies · $4,965 in 2025
The $4,965 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.33 · 2021: $113 · 2022: $812 · 2023: $1,139 · 2024: $3,408 · 2025: $4,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,887 · Education: $2,517 · Food and Beverage: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,887.12 |
| Education | $2,517.38 |
| Food and Beverage | $1,107.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,600.94 | 2025 | |
| Medical Device Business Services, INC. | $3,423.80 | 2024-2025 | Monarch |
| Olympus Corporation of The Americas | $2,127.64 | 2023-2024 | Single Use Suction Valve (Sterile), Spiration Valve System, Vizishot 2 Flex |
| Pinnacle Biologics, INC | $643.80 | 2022 | |
| Glaxosmithkline, LLC. | $121.68 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $92.43 | 2021-2025 | Breztri |
| Ambu INC. | $92.15 | 2021 | |
| Electromed, INC. | $64.68 | 2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $63.55 | 2025 | Opsynvi, Uptravi |
| Pulmonx Corporation | $61.38 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Insmed, INC. | $41.27 | 2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $34.25 | 2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $26.95 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.55 | 2025 | Jascayd |
| Pfizer INC. | $21.10 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.42 | 2025 | Tezspire |
| E.R. Squibb & Sons, L.L.C. | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wallace Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.